News & Media Press releases & statements Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Apply filter Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Apply filter Year All Years 2023 2022 2021 2020 2019 2018 2017 2016 2015 Category All categories Type - Statement - Press release Topic - Corporate and finance - Global health - Partnerships Research area - COVID-19 - Ebola - RSV - Seasonal influenza Uncategorized Keywords Apply filter Advanced Search Search Search Headlines Only Type All Statement Press release Topic All Corporate and finance Global health Partnerships Research area All COVID-19 Ebola RSV Seasonal influenza From To Asset Types Photos Video Audio Documents Events Standard Jul 1, 2022 StatementGlobal healthCOVID-19 Novavax Statement on Prototype Vaccine’s Broad Immune Responses and Accelerated Focus on Omicron BA.4/5 as Recommended by the FDA Download Jun 28, 2022 COVID-19 Novavax COVID-19 Data Presented at FDA VRBPAC Meeting Demonstrates Broad Antibody Responses to Both Prototype and Omicron-Specific Variants Download Jun 28, 2022 StatementGlobal healthCOVID-19 Novavax to Participate in Vaccines and Related Biological Products Advisory Committee Review of COVID-19 Vaccines Strain Composition Download Jun 23, 2022 COVID-19 Novavax' Nuvaxovid™ COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan for Use in Individuals Aged 18 and Over Download Jun 23, 2022 COVID-19 Novavax COVID-19 Vaccine Nuvaxovid™ Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17 Download Jun 23, 2022 StatementGlobal healthCOVID-19 Novavax Files Supplement to a New Drug Submission in Canada for Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 Download Jun 17, 2022 StatementCOVID-19Seasonal influenza Novavax to Showcase Innovative Vaccine Data at Communicable Diseases & Immunisation Conference 2022 Download Jun 13, 2022 COVID-19 Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over Download Jun 7, 2022 COVID-19 FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older Download Jun 7, 2022 Corporate and financeCOVID-19 Novavax Statement on Stock Trading Halt; FDA Advisory Committee to Review Novavax’ COVID-19 Vaccine Download Show 5102550100 per page«1…6789101112…45»